Sai Parenterals FY26 PAT rises 45.5% to ₹14.37 Cr
Sai Parenterals reported FY26 PAT of ₹14.37 crore, up 45.5% YoY. Revenue surged 140% to ₹381 crore driven by CDMO exports.
*this image is generated using AI for illustrative purposes only.
Sai Parenterals Limited has announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a robust performance driven by CDMO exports and the integration of Noumed (Australia). For the full year FY26, the company recorded a Profit After Tax (PAT) of ₹14.37 crore, representing a growth of 45.52% compared to the previous year.
Consolidated Performance
For the financial year ended March 31, 2026, the company reported a revenue of ₹380.99 crore, a significant increase of 140.37% from ₹158.50 crore in FY25. Total income for the year stood at ₹389.51 crore. The company's EBITDA for FY26 was ₹47.21 crore, with a growth of 33.29% year-on-year. The board approved the results during a meeting on May 23, 2026.
| Metric | FY26 (₹ Cr) | FY25 (₹ Cr) | YoY Growth |
|---|---|---|---|
| Revenue | 380.99 | 158.50 | 140.37% |
| Total Income | 389.51 | 159.14 | 144.78% |
| EBITDA | 47.21 | 35.42 | 33.29% |
| PAT | 14.37 | 9.87 | 45.52% |
| EPS (INR) | 4.36 | 3.71 | 17.5% |
Quarterly Highlights
For the quarter ended March 31, 2026 (Q4 FY26), the consolidated revenue from operations was ₹197.93 crore, a jump of 166.65% compared to Q4 FY25. The net profit for the quarter surged to ₹13.25 crore, up 736.04% from ₹1.59 crore in the corresponding quarter of the previous year. EBITDA for the quarter stood at ₹28.97 crore, growing by 366.79%.
Standalone Results
On a standalone basis, Sai Parenteral's Limited reported a revenue of ₹164.99 crore for FY26, reflecting a growth of 30.65% year-on-year. The standalone PAT for the year was ₹16.86 crore, an increase of 63.61% from the previous year. The company attributed this growth to deeper engagement with customers in export markets.
Business and Strategic Updates
The company highlighted the successful acquisition of a 74.6% controlling stake in Australia-based Noumed Pharmaceuticals Pty Limited on November 12, 2025. This acquisition provides access to 451 dossiers and strengthens the company's position in the Australian market. Additionally, Sai Parenterals successfully completed its IPO in March 2026, raising ₹285 crore, and listed on the exchanges on April 02, 2026. The company is executing a capex program of approximately ₹440 crore, expected to be completed by FY27, to support capacity expansion and R&D.
Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE0H9F01037/baf46b29-934e-4c11-b52b-5362be77077b.pdf
Historical Stock Returns for Sai Parenteral's
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.26% | +1.06% | -0.23% | +19.21% | +19.21% | +19.21% |
How will the ₹440 crore capex program specifically enhance R&D capabilities and production capacity once completed in FY27?
What strategies will be employed to leverage the 451 dossiers acquired from Noumed to expand into other regulated international markets?
How does the company plan to utilize the ₹285 crore raised via the IPO to accelerate growth beyond the current capacity expansion?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
